Logotype for Tilray Brands Inc

Tilray Brands (TLRY) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Tilray Brands Inc

Q2 2026 earnings summary

13 Apr, 2026

Executive summary

  • Achieved record Q2 net revenue of $218 million, up 3% year-over-year, with strong international cannabis and Canadian adult-use growth, surpassing analyst expectations despite industry headwinds.

  • Operating loss narrowed to $22.3 million from $42.2 million in the prior year, with net loss improving by $41.8 million to $(43.5) million and adjusted net loss per share improving to $(0.02).

  • Ended the quarter with $292 million in cash and marketable securities, achieving a net cash position of nearly $30 million.

  • Diversified operations across cannabis, beverage, and wellness, with leading market positions in Canada and significant presence in the U.S. and Europe.

  • Completed a one-for-ten reverse stock split effective December 2, 2025.

Financial highlights

  • Net revenue for Q2 was $217.5 million, driven by international cannabis and distribution, with Canadian adult-use revenue up 6% year-over-year.

  • Cannabis net revenue reached $67.5 million, beverage net revenue was $50.1 million (down 21% year-over-year), distribution net revenue was $85.3 million (up 26%), and wellness net revenue was $14.6 million.

  • Gross profit was $57.5 million with a gross margin of 26%; cannabis gross margin increased to 39%, beverage 31%, distribution 13%, and wellness 32%.

  • Net loss for the quarter was $43.5 million, a significant improvement from $85.3 million in the prior year.

  • Cash flow used in operations improved to $8.5 million from $40.7 million last year.

Outlook and guidance

  • Reaffirmed full-year 2026 adjusted EBITDA guidance of $62 million to $72 million.

  • Anticipates continued growth in international cannabis and distribution, with spring product resets expected to benefit beverage revenue and margins in Q4.

  • Positioned to capitalize on U.S. cannabis rescheduling and global regulatory shifts, with readiness to scale medical cannabis operations.

  • Ongoing focus on SKU rationalization, geographic and distributor optimization, and synergy realization in the beverage segment.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more